Fig. 5

PCDH19 expression in the hippocampal CA1 and DG of epileptic mice. A Detection of the endogenous PCDH19 protein (red) in CA1 by immunofluorescent labeling. Neurons were labeled by the neuronal marker, NeuN (green). Scale bar, 100 μm. B Analysis of fluorescence intensity was performed using ImageJ. Differences in the relative fluorescence intensity (PCDH19 vs. NeuN) were analyzed with the Students t-test (Control: 0.987 ± 0.006, 60 days: 0.947 ± 0.012, n = 3, p = 0.015). C Detection of PCDH19 protein (red) and NeuN (green) in DG by immunofluorescent labeling. Scale bar, 100 μm. D Analysis of fluorescence intensity was performed using ImageJ. Differences in the relative fluorescence intensity (PCDH19 vs. NeuN) were analyzed with the Students t-test (Control: 0.967 ± 0.010, 60 days: 0.693 ± 0.024, n = 3, p < 0.0001). The data are expressed as mean ± SEM and analyzed with unpaired Student’s t-test. **p < 0.01, *p < 0.05, ****p < 0.0001. E The levels of PCDH19 protein at different time points following pilocarpine-induced SE. F Comparison of PCDH19 blots density between control mice and epileptic mice at each time point after SE (n = 3 per group). Bmal1 expression was significantly decreased at 14 days (0.480 ± 0.046) and 60 days (0.522 ± 0.119), compared with Ctrl (0.960 ± 0.028). The data are expressed as mean ± SEM and analyzed with one-way ANOVA, **p < 0.01